Related references
Note: Only part of the references are listed.Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Nicolas Girard et al.
JOURNAL OF THORACIC ONCOLOGY (2023)
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Jarushka Naidoo et al.
JOURNAL OF THORACIC ONCOLOGY (2023)
Original Article Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study
E. K. Donovan et al.
CLINICAL ONCOLOGY (2023)
Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
Yu Wang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial
Cecile Le Pechoux et al.
LANCET ONCOLOGY (2022)
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Qing Zhou et al.
LANCET ONCOLOGY (2022)
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
D. Gale et al.
ANNALS OF ONCOLOGY (2022)
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2022)
Radiomics for Predicting Lung Cancer Outcomes Following Radiotherapy: A Systematic Review
G. M. Walls et al.
CLINICAL ONCOLOGY (2022)
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer
Parisa Forouzannezhad et al.
CANCERS (2022)
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Marina C. Garassino et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
M. Provencio et al.
Journal of Thoracic Oncology (2022)
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial
Yufei Liu et al.
LUNG CANCER (2022)
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer
Daniel Sentana-Lledo et al.
LUNG CANCER (2022)
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Jamie E. Chaft et al.
NATURE MEDICINE (2022)
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial)
Juwhan Choi et al.
THORACIC CANCER (2022)
IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
C. Zhou et al.
ANNALS OF ONCOLOGY (2021)
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress
Shun Lu et al.
CLINICAL LUNG CANCER (2021)
Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer
Katelyn M. Atkins et al.
JAMA ONCOLOGY (2021)
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Ana Casal-Mourino et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
Solange Peters et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
Kathryn Banfill et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Jacqueline V. Aredo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone et al.
NATURE MEDICINE (2021)
95TiP DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, stage III NSCLC ineligible for chemotherapy
A.R. Filippi et al.
Journal of Thoracic Oncology (2021)
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
Nasser K. Altorki et al.
LANCET ONCOLOGY (2021)
Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis
Qiuying Chen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy The Phase 3 PORT-C Randomized Clinical Trial
Zhouguang Hui et al.
JAMA ONCOLOGY (2021)
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status A Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2021)
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
Jeffrey D. Bradley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
Ursula Nestle et al.
LANCET ONCOLOGY (2020)
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2020)
Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
B. Besse et al.
ANNALS OF ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2019)
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer
Katelyn M. Atkins et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Gideon M. Blumenthal et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications
Wanyin Lim et al.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY (2018)
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Aadel A. Chaudhuri et al.
CANCER DISCOVERY (2017)
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer
Suresh Senan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis
David E. Dawe et al.
LUNG CANCER (2016)
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
W. E. E. Eberhardt et al.
ANNALS OF ONCOLOGY (2015)
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
Wilfried Ernst Erich Eberhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
Jin Seok Ahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Walter J. Curran et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S. Albain et al.
LANCET (2009)
Impact of postoperative radiation therapy on survival in patients with complete resection and Stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial
Jean-Yves Douillard et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multimodality therapy for stage III non-small-cell lung cancer
D Farray et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)